Business Context and Reporting Period
This Form 8-K Current Report was filed by Prothena Corporation plc on August 30, 2022. The registrant is incorporated in Ireland and its ordinary shares trade on the Nasdaq Global Select Market under the symbol PRTA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The Board of Directors increased the size of the Board and appointed Helen S. Kim as a director, effective immediately on August 30, 2022.
Guidance, Outlook, and Management Commentary
- Compensation: Ms. Kim will receive director fees and equity-based compensation consistent with the standard arrangements for non-employee directors disclosed in the Company's 2022 proxy statement.
- Indemnification: Ms. Kim and the Company will enter into the Company's standard Deed of Indemnification.
- Conflicts of Interest: There are no arrangements or understandings regarding her selection, and she holds no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the specific terms of the director fees and equity compensation in the 2022 Annual General Meeting proxy statement.
- Review the standard Deed of Indemnification filed as an exhibit to the December 11, 2014 Form 8-K.
- Confirm the updated composition of the Board of Directors on the Company's investor relations website.